SCHEMBL2849503

SCHEMBL2849503

C=Cc1ccc(COc2cc(CO)c(O)c(CO)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.41
CYP1A1 P04798 1/20 0.41
CYP19A1 P11511 1/20 0.41
HIF1A Q16665 2/20 0.40
CASP3 P42574 2/20 0.37
SENP8 Q96LD8 2/20 0.37
SENP7 Q9BQF6 2/20 0.37
SENP6 Q9GZR1 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
PKM P14618 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37
PLEC Q15149 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL439247 0.83 SMN1; SMN2 (0.43) CYP1A2CYP1A1CYP19A1HIF1ACASP3
SCHEMBL6394555 0.82 ALDH1A1 (0.46) CYP1A2CYP1A1CYP19A1HIF1ACASP3
SCHEMBL7628720 0.81 SMN1; SMN2 (0.42) CYP1A2CYP1A1CYP19A1HIF1ACASP3
SCHEMBL3241768 0.79 NPC1 (0.47) CYP1A2HIF1ACASP3SENP8SENP7
SCHEMBL2854281 0.78 ERN1 (0.42) CYP1A2CYP1A1CYP19A1HIF1AMAPT
SCHEMBL2849932 0.77 APP (0.59) CYP1A2CYP1A1CYP19A1HIF1ACASP3
SCHEMBL6388039 0.76 APP (0.54) CASP3SENP8SENP7SENP6ALDH1A1
SCHEMBL13242652 0.76 APP (0.54) CASP3SENP8SENP7SENP6ALDH1A1
SCHEMBL14771366 0.76 HIF1A (0.44) CYP1A2CYP1A1CYP19A1HIF1AMAPT
SCHEMBL18959614 0.74 RXRA (0.45) CYP1A2CYP1A1CYP19A1HIF1ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204038-A1 Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid CARLONI SILVIA 2010-08-12 US disclosed
EP-1765496-B1 CATALYSTS BASED ON COPPER COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA SPA (IT) 2010-07-14 EP disclosed
US-7723539-B2 Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid ENDURA S.P.A. (IT) 2010-05-25 US disclosed
US-20080021237-A1 Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid ENDURA S.P.A. (IT) 2008-01-24 US disclosed
EP-1765496-A1 CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA S.p.A. (IT) 2007-03-28 EP disclosed
WO-2005123254-A1 CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA S.P.A. (IT) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021237-A1 Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid SCO2, ME1, ME3 CYP1A2 1258/4885CYP1A1 1662/4885CYP19A1 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.